^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TGI-2

    i
    Other names: TGI-2, NM1F, TGI-2/NM1F
    Associations

    News

    Trials
    Company:
    TG ImmunoPharma
    Drug class:
    PVRIG inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, Hefei TG ImmunoPharma Co., Ltd. | Withdrawn --> Recruiting | Trial completion date: Jun 2023 --> Sep 2027 | Trial primary completion date: Jun 2023 --> Sep 2027
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • TGI-2
    12ms
    A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=0, Withdrawn, Hefei TG ImmunoPharma Co., Ltd. | N=38 --> 0 | Trial completion date: Sep 2026 --> Jun 2023 | Recruiting --> Withdrawn | Trial primary completion date: May 2026 --> Jun 2023
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • TGI-2
    over1year
    A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, Hefei TG ImmunoPharma Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • TGI-2